In vivo, treatment of pancreatic xenografts with gemcitabine also resulted in a significant decrease in tumor volume, but an enrichment of the CD133+ cell fraction, suggesting that CSCs play a role in treatment resistance [90]. Here, PROM1 is linked to neoplasm.